CreativeOne Wealth LLC Raises Position in Insulet Corporation $PODD

Key Points

• CreativeOne Wealth LLC increased its stake in Insulet Corporation by 44.3%, acquiring 1,697 shares and bringing its total holdings to 5,532 shares, valued at approximately $1,453,000.
• Insulet's stock has received a consensus rating of "Moderate Buy" from analysts, with a price target of $332.71, following strong quarterly earnings that exceeded expectations.
• During the last quarter, several firms, including Brooklyn Investment Group and Cooper Financial Group, also increased their positions in Insulet, highlighting growing interest among large investors.

CreativeOne Wealth LLC grew its holdings in Insulet Corporation (NASDAQ:PODD - Free Report) by 44.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,532 shares of the medical instruments supplier's stock after purchasing an additional 1,697 shares during the quarter. CreativeOne Wealth LLC's holdings in Insulet were worth $1,453,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PODD. Larson Financial Group LLC raised its holdings in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation National Association UT bought a new stake in shares of Insulet in the 1st quarter valued at about $26,000. SouthState Corp raised its holdings in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after purchasing an additional 76 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in shares of Insulet in the 4th quarter valued at about $42,000. Finally, Ramirez Asset Management Inc. bought a new stake in shares of Insulet in the 1st quarter valued at about $53,000.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PODD. Royal Bank Of Canada boosted their price target on shares of Insulet from $330.00 to $350.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Canaccord Genuity Group upped their price target on Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Citigroup restated a "buy" rating on shares of Insulet in a research note on Tuesday, July 8th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $360.00 price target (up from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Sixteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $332.71.

Insulet Stock Performance

Shares of NASDAQ PODD traded down $3.92 during trading on Wednesday, reaching $341.01. 335,701 shares of the company traded hands, compared to its average volume of 755,035. Insulet Corporation has a 12-month low of $204.02 and a 12-month high of $350.00. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The stock has a market cap of $24.00 billion, a P/E ratio of 103.61, a PEG ratio of 2.85 and a beta of 1.36. The firm's fifty day simple moving average is $305.37 and its 200 day simple moving average is $288.52.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's quarterly revenue was up 32.9% on a year-over-year basis. During the same period last year, the business earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.